H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Immunogen on Tuesday, setting a price target of $12, which is approximately 84.33% above the present share price of $6.51.
Ramakanth expects Immunogen to post earnings per share (EPS) of $0.17 for the second quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Moderate Buy rating of shares in ImmunoGen (NASDAQ:IMGN), with an average price target of $10.17.
The analysts price targets range from a high of $12 to a low of $6.5.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $85.8 million and a net profit of $36.48 million. The company's market cap is $1.3 billion.
According to TipRanks.com, H.C. Wainwright analyst Swayampakula Ramakanth is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 29.3% and a 47.62% success rate.
ImmunoGen, Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779 and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA.